Stay updated on Pembrolizumab for Genomic Instability Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Genomic Instability Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.1 to v3.4.2. Core study details, eligibility criteria, and contact information appear unchanged.
    Difference
    0.1%
    Check dated 2026-02-12T01:54:34.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    A minor revision update from v3.4.0 to v3.4.1 is shown; no other content changes are observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-04T23:39:21.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The page now includes a Show glossary option and new QC metadata labels, including Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0, replacing the prior Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-28T21:18:26.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    The page revision updated from v3.3.3 to v3.3.4. No study data, eligibility criteria, or locations were modified. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-14T03:48:50.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Added location sections for New Jersey and New York. Removed the separate 'New Jersey Locations' and 'New York Locations' blocks and updated the revision to v3.3.3.
    Difference
    0.3%
    Check dated 2025-12-23T21:57:05.000Z thumbnail image
  6. Check
    68 days ago
    Change Detected
    Summary
    Removed the 'Last known status' section and the entry for Eugenia Girda, MD, Rutgers Cancer Institute of New Jersey.
    Difference
    0.4%
    Check dated 2025-12-09T19:03:32.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Genomic Instability Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Genomic Instability Clinical Trial page.